Browse Biotechnology industry topic

Product development subtopic

Articles 1-100 out of 100 article(s) Title Author Type Date Words Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors. Nov 23, 2009 1068 Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder. Nov 18, 2009 374 Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA. Nov 17, 2009 2326 Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75. Nov 16, 2009 705 United States : Esperion Therapeutics Initiates Phase I Clinical Study For ETC-1002. Nov 15, 2009 294 United states : Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results At CTOS Annual Meeting. Clinical report Nov 9, 2009 387 United States : ABRAXANE(R) Receives Orphan Drug Status For The Treatment Of Pancreatic Cancer And Stage IIB-IV Melanoma. Nov 9, 2009 269 Lin Horn Tech pushes nano-ag anti-bacteria biomedical material. Brief article Nov 6, 2009 178 ABRAXANE[R] Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma. Nov 5, 2009 686 NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer[R] NOX-A12. Nov 2, 2009 736 Juvaris BioTherapeutics Initiates Phase 2 Study of Influenza Vaccine Adjuvant in Elderly Population. Nov 2, 2009 594 United States : Human Genome lupus drug succeeds in BLISS-76 trial. Nov 2, 2009 390 United States : Advaxis Receives IRB Approval For Cervical Dysplasia Trial Of ADXS11-001. Oct 30, 2009 355 Advaxis Receives IRB Approval for Cervical Dysplasia Trial Of ADXS11-001. Oct 28, 2009 698 PolyMedix Completes Successful Phase 1B Clinical Study of Heparin Antagonist PMX-60056. Oct 27, 2009 1524 Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer. Oct 23, 2009 1530 Human Genome Sciences and GlaxoSmithKline Announce Full Presentation at ACR of Positive Phase 3 Study Results for BENLYSTA[TM] in Systemic Lupus Erythematosus. Oct 20, 2009 2992 First Patient Enrolled in Phase 3 Trials of Genzyme Oral Capsule for Gaucher Disease. Clinical report Oct 20, 2009 928 Switzerland : DEWB investment holding NOXXON Pharma AG announces excellent preliminary phase I trial results for Spiegelmer[R] NOX-E36. Oct 14, 2009 280 NOXXON Pharma AG Announces Excellent Preliminary Phase I Trial Results for Spiegelmer[R] NOX-E36 - Good Safety and Pharmacodynamic Profile and Additional Good Subcutaneous Bioavailability. Oct 12, 2009 705 With cash on hand growing short, Transdel seeks a partner: Lo Jolla firm has burned through $13.2 million pursuing lead drug candidate. Chambers, Heather Oct 12, 2009 614 Seattle Genetics Announces Discontinuation of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial. Oct 5, 2009 749 Avila Presents Preclinical Data on its Novel, Orally-Available, Pan-Genotype Protease Inhibitor, AVL-181, Demonstrating Protein Silencing of Hepatitis C Virus. Oct 5, 2009 671 United States : Oncolytics' Phase III Borrows Adaptive Design in SPA Trial. Oct 3, 2009 493 Updated Advaxis Phase I Survival Data Indicates Long-Term Immune Protection. Oct 1, 2009 671 HAWAII BIOTECH BEGINS PHASE 1 CLINICAL TRIAL FOR DENGUE VACCINE. Oct 1, 2009 502 Can-Fite Initiates Preparatory Work for Psoriasis Phase III Trial with CF101. Clinical report Sep 30, 2009 500 PolyMedix Initiates Dosing in Phase 1B Clinical Study of Novel Anticoagulant Antagonist Compound. Sep 29, 2009 852 Genzyme's Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia. Sep 24, 2009 1384 Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy Results for LX214, a Potential Best-in-Class Treatment for Dry Eye. Financial report Sep 23, 2009 1196 Bioheart Inc. Announces Positive Results in the MARVEL Phase II/III Clinical Trial. Sep 16, 2009 2004 Disappointing clinical trial pummels Acadia: data suggests drug could have other applications. Chambers, Heather Sep 14, 2009 672 Genzyme's Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data. Sep 11, 2009 2380 Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101. Clinical report Sep 8, 2009 653 Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration With Bayer Schering Pharma. Sep 8, 2009 700 Acadia shares slump on clinical trial results. Chambers, Heather Brief article Sep 7, 2009 129 Novel Evidence-Based Systemic Lupus Erythematosus (SLE) Responder Index Described in Peer Reviewed Publication as Potentially Significant Advance in Lupus Drug Development. Sep 4, 2009 1644 ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis. Sep 1, 2009 1069 FDA Advisory Committee Recommends Randomized Trial to Support Proposed Indication for Clolar in Adult AML. Clinical report Sep 1, 2009 1290 United Kingdom : NovaBiotics targets [pounds sterling]3bn market after fungus treatment trials. Sep 1, 2009 348 Research and Markets: Emerging Clinical Trial Locations: Market Dynamics and the Changing Healthcare and Regulatory Environment. Aug 26, 2009 641 United States : Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin. Aug 25, 2009 476 Israeli Firm Reports Success for Swine Flu Vaccine. Aug 25, 2009 84 Seattle Genetics Completes Enrollment of Brentuximab Vedotin (SGN-35) Pivotal Trial for Patients with Hodgkin Lymphoma. Aug 24, 2009 1249 United States : Sinovac Biotech announces positive results from clinical trial of H1N1 vaccine. Aug 19, 2009 432 Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with MedImmune. Aug 10, 2009 654 Results from a Phase 2 Study of ABRAXANE[R] In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer. Conference news Aug 3, 2009 1700 ACT BIOTECH Announces Treatment of First Gastric Cancer Patients with Telatinib in a Phase 2 Clinical Trial in the U.S. and Spain. Jul 30, 2009 546 Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial. Jul 24, 2009 763 Abraxis BioScience Completes Enrollment of Pivotal Phase III Advanced Lung Cancer Study Evaluating ABRAXANE[R] Vs. Taxol[R]. Clinical report Jul 14, 2009 1711 Maxygen Announces Positive Results of MAXY-G34 Phase IIa Study in Breast Cancer Patients. Clinical report Jul 14, 2009 1391 Intellikine raises $51m in quest for cancer drug. Chambers, Heather Brief article Jul 13, 2009 182 New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. Jul 13, 2009 1202 Advaxis Engages the Numoda Corporation to Oversee Phase II Clinical Trials of ADXS11-001. Jun 23, 2009 462 Avir Green Hills: Excellent Preclinical Data on Novel Type of Intranasal H5N1 Influenza Vaccine - Technology Also Suitable for Vaccination against Swine Flu. Jun 19, 2009 769 Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma. Jun 18, 2009 862 OPKO Invests in Biotechnology Company with Novel Approach to Developing New Drugs. Jun 15, 2009 462 Seattle Genetics Reports Data from SGN-35 Every Three Week Dosing Phase I Trial in Lymphoma. Jun 8, 2009 937 NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer[R]. Jun 8, 2009 447 Seattle Genetics Presents Final Lintuzumab Phase I Clinical Data. Jun 8, 2009 924 PolyMedix Initiates Dosing in Second Phase I Clinical Study of Novel Systemic Antibiotic Compound. Jun 5, 2009 1295 New Data from Satraplatin Phase 3 Trial in Second-Line Castrate-Refractory Prostate Cancer Presented at 2009 ASCO Annual Meeting. Jun 2, 2009 1189 ASCO Presentations Highlight Findings from Clinical Trials with ArQule's c-MET Inhibitor, ARQ 197. Jun 1, 2009 2442 Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma. Jun 1, 2009 1265 Can-Fite-Completed Patient Enrollment for the Phase II Trial in Psoriasis With CF101. Clinical report Jun 1, 2009 533 Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL147, a Selective Inhibitor of PI3K. Jun 1, 2009 1118 Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL765, a Dual Inhibitor of PI3K and mTOR. Jun 1, 2009 1081 Pipeline help: Amgen Inc. is paying partner Cytokinetics Inc. $50 million for rights to its heart-drug program, which includes a promising experimental drug. Brief article Jun 1, 2009 90 Fate tests experimental drug: treatment would help replenish blood systems. Chambers, Heather Jun 1, 2009 471 Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase II Data at ASCO Annual Meeting. May 31, 2009 1426 Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma Multiforme. May 31, 2009 1321 Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer. May 30, 2009 1676 Data from the Phase III ATLAS Study Show Tarceva in Combination with Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer. Clinical report May 30, 2009 1208 Exelixis Reports Encouraging Phase 1 Data to Be Presented at ASCO for XL228, a Multi-Targeted Inhibitor of Key Cancer Signaling Kinases. May 30, 2009 1053 PolyMedix Receives Regulatory Clearance to Initiate Second Phase I Clinical Study of Novel Systemic Antibiotic Compound. May 21, 2009 1178 Seattle Genetics to Present SGN-35 and Lintuzumab Clinical Data at the European Hematology Association Congress. May 21, 2009 753 Pervasis Therapeutics Presents Promising Preclinical Data for its Minimally Invasive Cell Therapy at the European Association of Percutaneous Cardiovascular Interventions Annual Congress (EuroPCR). May 19, 2009 994 Can-Fite Announces Positive Results From Its Phase II Trial Treating Keratoconjunctivitis Sicca (Dry Eye Syndrome) With CF101. May 18, 2009 743 Seattle Genetics Announces SGN-35 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting. May 14, 2009 648 Cellerant Therapeutics Announces Dosing of First Patient in a Phase 1 Trial of CLT-008 for Hematological Malignancies. May 13, 2009 579 Pervasis Therapeutics to Present Preclinical Data on Novel, Minimally Invasive Cellular Therapy at the European Association of Percutaneous Cardiovascular Interventions Annual Congress. May 12, 2009 328 ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis. Clinical report May 6, 2009 836 Setback for Sequenom: Sequenom. Chambers, Heather Brief article May 4, 2009 95 Atlas strengthens NSCLC treatments. Brief article May 1, 2009 240 Pulmatrix Announces Ph 1b/2a Clinical Trial of Novel iCALM Therapy for Flu. May 1, 2009 592 Cougar Biotechnology Initiates Phase III Trial of CB7630 (Abiraterone Acetate) in Chemotherapy-Naove Castration-Resistant Prostate Cancer Patients. Apr 29, 2009 737 Avila Presents Preclinical Data on a Novel, Orally-Available, Protease Inhibitor, AVL181, for Hepatitis C Infection at EASL 2009 Meeting. Apr 27, 2009 844 Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs at AACR. Apr 22, 2009 828 BIO Members Committed to Ensuring Public Access to Key Clinical Trial Results. Apr 20, 2009 459 Dendreon to reveal results of Provenge clinical trial; Prostate-cancer treatment; Shares up 113 percent amid speculation over study. Apr 14, 2009 314 Biotech seeking to disrupt how bacteria communicate. Chambers, Heather Apr 13, 2009 626 Traversa picks up series B funding. Allen, Mike Brief article Apr 13, 2009 93 Technology & life sciences. Brief article Apr 6, 2009 123 Probiotic-enhanced sweetener in development. Brief article Apr 1, 2009 71 Shot in the arm: ImmunoCellular Therapeutic Ltd. Mendoza, Lauren Alicia Brief article Mar 23, 2009 34 Cultivating cell culture. Grosvenor, Sally Report Sep 1, 2008 2587 MorphoSys and Novartis forge strategic alliance. Brief article Jan 1, 2008 267 OncoGenex Technologies. Brief article Sep 1, 2007 132 Systemic lupus erythematosis. Brief article Sep 1, 2007 58 CD83. Brief article Sep 1, 2007 79